Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics (ADXN)
NASDAQ:ADXN
Total Valuation
Addex Therapeutics has a market cap or net worth of $13.22M. The enterprise value is ―.
Market Cap$13.22M
Enterprise Value―
Share Statistics
Addex Therapeutics has 1,536,287 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,536,287
Owned by Insiders―
Owned by Institutions0.07%
Financial Efficiency
Addex Therapeutics’s return on equity (ROE) is -9.22 and return on invested capital (ROIC) is -508.33%.
Return on Equity (ROE)-9.22
Return on Assets (ROA)-2.27
Return on Invested Capital (ROIC)-508.33%
Return on Capital Employed (ROCE)-5.88
Revenue Per Employee70.13K
Profits Per Employee-458.97K
Employee Count23
Asset Turnover0.35
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Addex Therapeutics is -0.30. Addex Therapeutics’s PEG ratio is <0.01.
PE Ratio-0.30
PS Ratio0.00
PB Ratio2.75
Price to Fair Value2.75
Price to FCF-0.39
Price to Operating Cash Flow-0.39
PEG Ratio<0.01
Income Statement
In the last 12 months, Addex Therapeutics had revenue of 1.61M and earned -10.56M in profits. Earnings per share was -0.14.
Revenue1.61M
Gross Profit-5.32M
Operating Income-10.28M
Pretax Income-10.56M
Net Income-10.56M
EBITDA-10.23M
Earnings Per Share (EPS)-0.14
Cash Flow
In the last 12 months, operating cash flow was -5.97M and capital expenditures -2.48K, giving a free cash flow of -5.97M billion.
Operating Cash Flow-5.97M
Free Cash Flow-5.97M
Free Cash Flow per Share-3.89
Dividends & Yields
Addex Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.04
52-Week Price Change-7.65%
50-Day Moving Average7.63
200-Day Moving Average8.47
Relative Strength Index (RSI)58.49
Average Volume (3m)6.67K
Important Dates
Addex Therapeutics upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateApr 25, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Addex Therapeutics as a current ratio of 1.46, with Debt / Equity ratio of 0.40%
Current Ratio1.46
Quick Ratio1.46
Debt to Market Cap0.00
Net Debt to EBITDA0.34
Interest Coverage Ratio-475.83
Taxes
In the past 12 months, Addex Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Addex Therapeutics EV to EBITDA ratio is -36.61, with an EV/FCF ratio of -46.81.
EV to Sales232.15
EV to EBITDA-36.61
EV to Free Cash Flow-46.81
EV to Operating Cash Flow-46.85
Balance Sheet
Addex Therapeutics has $3.35M in cash and marketable securities with CHF0.00 in debt, giving a net cash position of -$3.31M billion.
Cash & Marketable Securities$3.35M
Total DebtCHF0.00
Net Cash-$3.31M
Net Cash Per Share-$2.15
Tangible Book Value Per Share$0.02
Margins
Gross margin is -177.37%, with operating margin of -637.42%, and net profit margin of -654.47%.
Gross Margin-177.37%
Operating Margin-637.42%
Pretax Margin-654.47%
Net Profit Margin-654.47%
EBITDA Margin-634.16%
EBIT Margin-653.13%
Analyst Forecast
The average price target for Addex Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-70.05%
EPS Growth Forecast―